Advertisement

 

 

Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.

Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.
Author Information (click to view)

Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, Höller K, Sierra S, Knops E, Kaiser R, Scheid C, Di Cristanziano V,


Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, Höller K, Sierra S, Knops E, Kaiser R, Scheid C, Di Cristanziano V, (click to view)

Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, Höller K, Sierra S, Knops E, Kaiser R, Scheid C, Di Cristanziano V,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Medical microbiology and immunology 2017 07 12() doi 10.1007/s00430-017-0511-4

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment option for several hematological diseases. However, the first year post-transplantation is often complicated by infections and graft-versus-host disease (GVHD). Improvements in immunological monitoring could reduce such post-transplant complications. Torque Teno virus (TTV), a chronically persisting DNA virus, is reported to be a marker for immune function in immunocompromised patients. In the present study, the TTV kinetics were analyzed to investigate the potential role of TTV viremia as immune-competence read-out after allo-HSCT. Twenty-three monocentric allo-HSCT recipients were retrospectively tested for TTV-DNA in whole blood at given day post-transplant. Dynamics of TTV viremia was analyzed with respect to episodes of non-TTV viral reactivations (CMV, EBV, and BKPyV), acute GVHD, and recovery of immune cells. Recipients affected by persisting viral infections and/or GVHD during the first 100 days after allo-HSCT showed a significantly higher median TTV load at day +30 than patients with a less complicated clinical course (p = 0.005). This was also associated with a total lymphocyte count <5.5E+08 cells/L in this high-risk group (p = 0.039). These findings suggest that TTV could represent an additional parameter to identify patients at higher risk for complications in the first 100 days following allo-HSCT. Prospective studies, including the monitoring of lymphocyte subsets, are required to define the potential use of TTV in immunological monitoring after allo-HSCT.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 + 5 =

[ HIDE/SHOW ]